Immunologic Factor
sipuleucel-T
sipuleucel·T
Brand Names:
Provenge
Effect:
Increased Immunologic Activity
May Treat:
Prostatic Neoplasms
More Information:
Definitions related to sipuleucel-t:
-
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)NCI ThesaurusU.S. National Cancer Institute, 2021
-
A drug used to treat prostate cancer that has spread. It is made from immune system cells collected from a patient with prostate cancer. The cells are treated with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Provenge is a type of vaccine and a type of cellular adoptive immunotherapy.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> S
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.